← Back to Torch Briefings

Copay Accumulator and Maximizer Programs in Self-Funded Health Plans for 2026

Published by Ryan Mefford | October 26, 2026 | Part of the Torch Briefings series

For a self-funded employer, the fastest-growing line in the health plan is specialty pharmacy, and the tools built to manage it have quietly become standard equipment. Copay accumulator and maximizer programs now touch a large share of commercial coverage — by one widely cited analysis, close to four in ten commercially insured people were in a plan using an accumulator or a maximizer by late 2025. For a plan sponsor that owns its claims risk, these are not vendor features to rubber-stamp — they are design decisions with real fiduciary weight and real consequences for employees filling a prescription.

What the two programs actually do

Both start from the same place: manufacturer copay assistance, the coupons and cards that help a patient afford an expensive specialty drug. An accumulator changes how that assistance is counted. Ordinarily, a copay card’s value would apply toward the patient’s deductible and out-of-pocket maximum; an accumulator program stops it from counting. The patient uses the coupon, the plan does not credit it, and when the manufacturer’s assistance is exhausted, the patient suddenly faces the full remaining deductible — often thousands of dollars, and often as a surprise at the pharmacy counter.

A maximizer takes a different route. It spreads the manufacturer’s maximum annual assistance evenly across the plan year and classifies the drug as non-essential, which lets the plan capture the full manufacturer benefit while the patient pays little or nothing at the point of sale. The patient’s immediate experience is better than under an accumulator, but the mechanism shifts the drug’s cost onto the manufacturer’s program — and the vendor orchestrating it is paid for the service, with fees reported at 25% or more of the manufacturer assistance captured, not always transparently to the sponsor.

How common they have become

The adoption data tells the story of a tool that moved from the margin to the mainstream. By 2025, roughly 84% of commercially insured beneficiaries were in plans where an accumulator was available in the design and about 81% in plans with a maximizer available — though a smaller share, around 39%, were in plans that had actually implemented an accumulator, with a comparable figure for maximizers. The gap between available and implemented is where the sponsor’s choice lives — the design sits in most plans, waiting on a decision the sponsor, not the vendor, is accountable for.

Why the self-funded sponsor owns this decision

Here is the distinction that matters most for a self-funded employer. A growing number of states — New Jersey became the twenty-sixth in January 2026 — have passed laws requiring plans to count copay assistance toward a patient’s cost-sharing, effectively restricting accumulators. But those laws reach only fully-insured and marketplace plans. ERISA preempts state insurance regulation of self-insured plans, so a self-funded employer can still run an accumulator in a state where a fully-insured employer down the street cannot. By one estimate, about 17% of the commercial market — more than 34 million people — sits in plans that must count assistance; the self-funded majority is governed by the plan’s own design, not the state. That freedom is precisely why the responsibility lands on the sponsor.

The federal backdrop offers no clean answer either. A 2023 court decision vacated the HHS policy that had allowed accumulators for brand drugs without a generic equivalent, and HHS has neither finalized a replacement rule nor issued clarifying guidance since. The 2027 Notice of Benefit and Payment Parameters, released in proposed form in early 2026, did not resolve the question. A plan sponsor is therefore designing in a genuinely unsettled area, where the rules remain in motion.

The fiduciary and human stakes

None of this is merely administrative. Accumulators have been linked in multiple studies to lower adherence to specialty therapy — patients abandon treatment when the coupon lapses and the full deductible lands — and the burden falls hardest on lower-income and sicker members. Maximizers soften the point-of-sale cost but raise their own questions about transparency and the fees paid to the vendors that run them. For an ERISA plan sponsor, every one of those outcomes sits inside the fiduciary duty to administer the plan prudently and in participants’ interest, at a moment when fiduciary-breach litigation over pharmacy and cost decisions is rising. Choosing one of these programs is not just a cost lever; it is a decision a fiduciary should be able to document and defend.

This is the analysis our 4-Step Strategic Process is built to run. Strategic Discovery surfaces how specialty-drug cost actually moves through the plan and which members these programs would touch. Risk Assessment weighs the cost capture against the adherence risk, the fiduciary exposure, and the shifting federal and state rules. Solution Design structures the pharmacy strategy — accumulator, maximizer, alternative funding, or a more transparent arrangement — around that answer, with the vendor economics on the table. And Ongoing Optimization keeps the design aligned as the regulatory picture and the specialty pipeline keep changing.

A self-funded plan is, at bottom, a set of decisions the employer has chosen to own. Copay accumulators and maximizers are among the most consequential of those decisions — powerful cost tools, real burdens on patients, and a live fiduciary question at once. The sponsor that treats them as a deliberate, documented choice holds the plan in its own hands; the one that lets a vendor default decide is still accountable for the outcome, with none of the control.

Explore the PFTN Network

Captive insurance knowledge and expertise across multiple industries and sectors:

PFTN Risk

Risk management and captive insurance foundations

Contractors PFTN

Captives for construction and trade contractors

GovCon PFTN

Captive solutions for government contractors

Nonprofit PFTN

Risk management strategies for nonprofits and associations